Compare Boston Scientific Corporation (BSX) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Mongodb Inc — how do they compare? Boston Scientific Corporation trades at $43.29 (market cap $66.37B), while Mongodb Inc trades at $331.26 (market cap $27.72B). The key difference: Boston Scientific Corporation is far larger — about 2.4× Mongodb Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | MDB | |
|---|---|---|
Market Cap | $66.37B | $27.72B |
Sector | Health | Technology |
52-Week High | $108.14 | $440.25 |
52-Week Low | $42.63 | $201.08 |
Enterprise Value | $75.94B | $25.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
MongoDB (MDB) trades at $337.59, down 1.31% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. Revenue growth remains strong, reaching $2.01 billion in 2025, though the company is not yet profitable, posting a net loss of $129 million. Recent news highlights AI-driven demand boosting database sales, with the company raising FY2027 revenue guidance to $2.92–$2.96 billion, signaling robust growth prospects.
The outlook is positive given strong analyst support (81.8% buy ratings) and a $400.39 consensus price target, implying 18.6% upside. Key risks include ongoing losses, competitive pressures, and potential legal scrutiny from shareholder investigations. Earnings beats in recent quarters and projected narrowing losses by 2026 support a growth-oriented investment case, but profitability remains a critical watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
